Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial

Michael Wang, Preetesh Jain, Shuangtao Zhao, Hun Ju Lee, Loretta J. Nastoupil, Luis Fayad, Chi Young Ok, Rashmi Kanagal‐Shamanna, Holly A. Hill, Yixin Yao, Fredrick B. Hagemeister, Jason R. Westin, Nathan Fowler, Felipe Samaniego, Raphaël Steiner, Ranjit Nair, Swaminathan P. Iyer, Lucy Navsaria, Maria Badillo, Lei Feng, Huang Xuelin, Graciela M. Nogueras‐González, Guofan Xu, Nicolaus A. Wagner‐Bartak, Selvi Thirumurthi, David Santos, Guilin Tang, Pei Lin, Sa A. Wang, Jeff Jorgensen, C. Cameron Yin, Shaoying Li, Keyur P. Patel, Francisco Vega, L. Jeffery Medeiros, Christopher R. Flowers, Linghua Wang